| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 198,766 | 189,247 | 316,773 | 264,541 |
| Marketable securities, current | 153,616 | 152,670 | 67,162 | NaN |
| Accounts receivable | 20,000 | NaN | NaN | NaN |
| Prepaid expenses and other current assets | 7,397 | 7,800 | 7,367 | 6,609 |
| Total current assets | 379,779 | 349,717 | 391,302 | 271,150 |
| Total property and equipment, gross | NaN | 24,255 | NaN | NaN |
| Accumulated depreciation | NaN | 19,211 | NaN | NaN |
| Property and equipment, net | 4,682 | 5,044 | 5,538 | 6,006 |
| Restricted cash | 1,088 | 1,088 | 1,089 | 1,089 |
| Marketable securities, non-current | 10,556 | 18,114 | NaN | NaN |
| Operating lease right-of-use asset | 19,285 | 20,116 | 20,920 | 21,707 |
| Other assets | 4,320 | 3,048 | 3,209 | 3,567 |
| Total assets | 419,710 | 397,127 | 422,058 | 303,519 |
| Accounts payable | 4,013 | 1,794 | 2,918 | 3,666 |
| Accrued expenses and other current liabilities | 12,385 | 15,967 | 14,430 | 11,516 |
| Operating lease liabilities, current | 4,838 | 4,795 | 4,764 | 4,718 |
| Total current liabilities | 21,236 | 22,556 | 22,112 | 19,900 |
| Operating lease liabilities, net of current portion | 17,552 | 18,511 | 19,419 | 20,291 |
| 2026 | 0 | NaN | NaN | NaN |
| 2027 | 0 | NaN | NaN | NaN |
| 2028 | 0 | NaN | NaN | NaN |
| 2029 | 0 | NaN | NaN | NaN |
| 2030 | 33,602 | NaN | NaN | NaN |
| 2031 | 6,398 | NaN | NaN | NaN |
| Total future principal payments | 40,000 | NaN | NaN | NaN |
| Add end of term charge | 2,580 | NaN | NaN | NaN |
| Less unamortized discount and issuance costs | -3,747 | NaN | NaN | NaN |
| Less current portion of term loan | 0 | NaN | NaN | NaN |
| Term loan, non-current | 38,833 | NaN | NaN | NaN |
| Other liabilities, non-current | 388 | 1,094 | 1,091 | 1,090 |
| Total liabilities | 78,009 | 42,161 | 42,622 | 41,281 |
| Common stock, 0.001 par value 500,000,000 shares authorized as of march 31, 2026 and december 31, 2025 49,737,619 and 49,335,551 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively 10,372 shares subject to repurchase as of march 31, 2026 and december 31, 2025 | 50 | 49 | 48 | 44 |
| Additional paid-in-capital | 855,541 | 844,354 | 834,298 | 687,086 |
| Accumulated other comprehensive (loss) income | -135 | 110 | 69 | NaN |
| Accumulated deficit | -513,755 | -489,547 | -454,979 | -424,892 |
| Total stockholders' equity | 341,701 | 354,966 | 379,436 | 262,238 |
| Total liabilities and stockholders' equity | 419,710 | 397,127 | 422,058 | 303,519 |
Maze Therapeutics, Inc. (MAZE)
Maze Therapeutics, Inc. (MAZE)